OBJECTIVES: Mechanical circulatory support (MCS) with a ventricular assist device (VAD) as a bridge to heart transplantation (HTx) or recovery may improve outcome in children with terminal heart failure. We report our experience with MCS in children eligible for HTx and its effect on waiting list mortality.
INTRODUCTION
Heart failure is an important cause of morbidity and mortality in children. The majority of children are diagnosed with (idiopathic) dilating cardiomyopathy (iDCM) or congenital heart disease [1] . At presentation, 87% of children suffer from severe cardiac decompensation [2] . Estimates are that 50% of children with DCM die or undergo heart transplantation within 5 years after diagnosis [3, 4] . For children with medically incurable end-stage heart failure, heart transplantation is the only long-term therapeutic option. As donor availability is limited, children face a prolonged time on the waiting list. North American studies report a waiting list mortality of 25%, which is the highest in transplantation medicine [5, 6] .
In order to improve survival in patients with terminal heart failure who fail medical therapy, much effort has been put into the development of mechanical support of the circulation. Extracorporeal membrane oxygenation (ECMO) has successfully been used to sustain the circulation for several days to weeks, but has serious limitations in providing long-term support [7] .
Ventricular assist devices (VADs) are nowadays a well-accepted, long-term therapeutic option in adult end-stage heart failure [8] . Implementation of VADs in the paediatric population has been troublesome due to technical problems and difficulties in medical management. However, in recent years, several centres have presented their experience with Berlin Heart EXCOR VAD as longterm support. They have shown that Berlin Heart EXCOR VAD is a reliable and relatively safe device in bridging children to heart transplantation or recovery [9] [10] [11] [12] [13] .
Since 1998, our institute serves as a referral hospital in the Netherlands for end-stage heart failure and heart transplantation in children. Since 2006, the Berlin Heart EXCOR Pediatric VAD has become available in our hospital. The primary aim of this study is to describe the outcome of children supported with a VAD. Secondly, we aim to determine the effect of the introduction of the VAD on waiting list mortality.
METHODS

Patients
This study was approved by the local medical ethical committee (MEC 2014-525). All children listed for heart transplantation, as well as those who were eligible for heart transplantation at the time of VAD implantation at our centre, from 1 September 2006 to 31 July 2014 were included in the study. Medical records were retrospectively reviewed. In addition, medical records of patients listed for heart transplantation from 1998 to 1 September 2006 were reviewed to serve as historical control group of the era before the introduction of VADs. Primary end-points for analysis were all-cause mortality, heart transplantation and weaning from VAD. Serious adverse events (SAEs) were assessed in the VAD group only and consisted of the following: major bleeding, pericardial effusion requiring rethoracotomy, sepsis-infection, neurological dysfunction, thromboembolic and haemorrhagic complications, renal dysfunction, right heart failure, hepatic dysfunction, arterial non-central nervous system (CNS) thrombo-embolism, device malfunction, including confirmed pump thrombus requiring pump replacement and others (definitions adapted from INTERMACS) [14] . Demographic data were defined at listing for heart transplantation. In the VAD group, additional demographics, including INTERMACS profile, were determined at the time of VAD implantation. Glomerular filtration rate was estimated using the Schwartz formula [15] .
Ventricular assist devices and surgical procedure
The Berlin Heart EXCOR Pediatric VAD (Berlin Heart AG, Berlin, Germany) is a paracorporeal, pneumatically driven, polyurethane blood pump (stroke volumes of 10-25-30-50-60 ml), and can be implanted as left ventricular assist device (LVAD), right ventricular assist device or biventricular assist device (BiVAD).
All operations were performed through a standard median sternotomy using normothermic extracorporeal circulation. The heart was kept beating throughout the procedure. For LVAD, the inflow cannula was inserted at the left ventricular apex, the outflow cannula in the ascending aorta. Additional right atrial to main pulmonary artery cannulation was used in case BiVAD was required. In our hospital, it was standard to first connect the Berlin Heart EXCOR cannulae to a Centrimag Levitronix centrifugal pump (Levitronix GmbH, Zurich, Switzerland). In the initial phase of our paediatric VAD programme, this approach was primarily based on logistic reasons. The Levitronix pump can be connected to all sizes of Berlin Heart EXCOR cannulae; thus, only the different cannulae sizes had to be in stock. Furthermore, this policy allows for a less strict anticoagulatory regimen in case of actual or expected bleeding complications [16] . In the course of days, when patients were clinically stable and haemostasis was achieved, the Levitronix pump was changed for a matching Berlin Heart EXCOR ventricle.
Criteria for ventricular assist device implantation
In general, patients had to be eligible for heart transplantation [17] . Furthermore, the following criteria were applied: (i) deterioration of the circulation with increasing dosages of inotropes and/or development of metabolic acidosis, (ii) development of end-organ failure including inability to wean from respiratory support on the ventilator, signs of renal or hepatic damage and altered neurological state such as confusion. An individualized decision was made by the clinical team, based on these criteria and the rate of clinical deterioration.
Anticoagulation during ventricular assist device support
All children on VAD were treated with a standardized anticoagulation and antiplatelet regimen known as the Edmonton protocol [12, 18] . This protocol is developed by paediatric specialists in haematology, mechanical support, heart failure and surgery, and encompasses 15 years of experience with the Berlin Heart EXCOR worldwide. In general, children were treated with unfractionated heparin, low-molecular-weight heparin or warfarin, in combination with antiplatelet agents (dipyridamole and/or acetylsalicylic acid).
Weaning criteria
Children with ongoing improvement of myocardial function, laboratory parameters (declining N-terminal pro-BNP levels), echocardiographic signs of reverse remodelling and echocardiographic findings matching improvement of systolic function (opening of aortic valve, increasing shortening fraction) were considered for weaning. The pump flow was decreased by decreasing the pump rate as described by Stiller et al. [19] . Pump stops were evaluated by assessment of clinical haemodynamic parameters (e.g. blood pressure, peripheral perfusion), and the abovementioned echocardiographic parameters, followed by surgical explantation when weaning was tolerated well.
Statistical analysis
Statistical analysis was conducted with IBM SPSS statistics 21 (IBM, New York, USA). Continuous variables were expressed as medians (interquartile range) or numbers ( percentage). The independent median test was used to compare continuous variables, categorical analysis was conducted by χ 2 and Fisher's exact test. Mortality was compared between groups by Cox regression analysis. The level of significance was 0.05.
RESULTS
Patients
Data of 15 patients were collected over a study period from 1998 to 2006, the pre-VAD era (Cohort I), and data of 43 patients were collected from September 2006 to July 2014 (Cohort II). In Cohort II, 18 patients underwent implantation of a VAD (VAD group). Baseline clinical characteristics are described in Table 1 . There was no difference in age or weight between patients on VAD and non-VAD patients. VAD patients were more often diagnosed with iDCM. A glomerular filtration rate <30% of predicted was found in 2 patients (11%), 1 patient died while on VAD and in the other, renal function fully recovered after 7 days on VAD. A bilirubin above the upper level of normal was found in 65% of VAD patients. In the VAD group, 94% of patients were on inotropic support at the time of VAD implantation and 89% had an INTERMACS profile of I or II.
Ventricular assist device
Of the 18 implanted VADs, there were 16 LVADs and 2 BiVADs. In 6 cases, implantation of a VAD was preceded by ECMO followed by LVAD in 4 patients and BiVAD in 2 patients. Duration of ECMO in these 6 cases was 2.5 days median (IQR 1.0-10.3 days). In 3 cases, the rapidly deteriorating clinical condition precluded a suitable timeframe for direct implantation of a VAD; in 2 cases, patients were supported by ECMO in a 'crash' condition and 1 patient was referred to our hospital while already on ECMO. Median duration of treatment on Levitronix pump prior to placement of a Berlin Heart ventricle was 6 days (IQR 1.0-9.3 days). Three children were treated with a Levitronix system only. The first child died after 6 days in ongoing multiorgan failure. The other 2 were older children in whom we expected a short waiting time as they were waiting for larger donors. These 2 patients underwent successful transplantation after 10 and 13 days on MCS, respectively.
Primary end-points
In Cohort I, the pre-VAD era, 7/15 patients died (47%) and 8/15 patients were transplanted (53%), see Fig. 1 . In Cohort II, after the e Others consist of congenital heart diseases (n = 3) restrictive cardiomyopathy (cmp) (n = 6), hypertrophic cmp (n = 2), anthracycline induced cmp (n = 4), Beckers muscular dystrophy (n = 1) and rhythm disturbances induced cmp (n = 3). introduction of VADs, 9/43 patients died (21%) and 31/43 patients were transplanted (72%). Cox regression analysis showed a trend towards a significant reduction in waiting list mortality after the introduction of VAD (P = 0.08). In the VAD group of Cohort II, 9/18 patients were transplanted (50%), 7/18 patients died (38%; 2/2 BiVAD and 5/16 LVAD) and 2/18 patients were successfully weaned from VAD, one diagnosed with myocarditis and one with iDCM, after 30 and 308 days, respectively. Median time to death (n = 7) was 18 days (IQR 7-75), median time to bridge to heart transplantation (HTx) (n = 9) was 66 days (IQR 33-223). Of the 9 VAD patients undergoing heart transplantation, 1 died 3 years after transplantation, due to non-compliance with medical treatment. The most important causes of death for children who died on VAD were thromboembolic stroke (43%) and systemic thrombo-embolic events (29%), see Table 2 . One patient in the VAD group died while he was still on a Levitronix system.
In the non-VAD group of Cohort II, 22/25 patients were transplanted (88%), 2/25 patients died (8%) and 1 patient is still listed, no patients were delisted, see Fig. 1 . Median time to transplantation was 137 days (IQR 18-417). Regarding the two deaths in the non-VAD group, the parents of one patient refused implantation of a VAD, the parents of the other patient postponed their consent for VAD implantation until continued cardiopulmonary resuscitation was needed and implantation of a VAD was not achievable anymore. Comparing the VAD-group with the non-VAD patients, we found no difference in median time to death or transplantation.
The primary end-points are shown as competing events (Fig. 2) , depicting that the majority of end-points were reached in the first 100 days after VAD implantation. In Fig. 3 , survival of patients on VAD is shown.
Serious adverse events
The most common SAEs that occurred in the VAD patients are described in Table 3 . In 16/18 (89%) of patients, at least one SAE occurred. The most prevalent SAEs were confirmed thrombus requiring pump replacement in 11 patients (61%), neurological dysfunction in 7 patients (39%) and pericardial effusion requiring rethoracotomy in 5 patients (28%). Pump replacements occurred in 4/5 (80%) of children who died of a thrombo-embolic event. The median number of pump replacements was 1 per patient; in 4 patients the pump was replaced three times or more. In those 4 patients, median time on VAD was 306 days, they all survived. The range of Berlin Heart EXCOR ventricle sizes was 10-60 ml: 1 ventricle of 10 ml, 6 ventricles of 25 ml, 1 ventricle of 30 ml, 5 ventricles of 50 ml, 2 ventricles of 60 ml and 3 children were assisted with a Levitronix system only. Considering children below 15 kg as 'small patients', our series included 5 small patients (4 with 25 ml ventricle, 1 with a 10-ml ventricle) of which 3 patients developed a thrombo-embolic stroke.
Of the 7 patients with thrombo-embolic stroke or intracranial bleeding, 4 died and 3 suffered from neurological disability. In the latter 3, the degree of neurological damage did not preclude heart transplantation. Follow-up data of 8, 3 and 2.5 years, respectively after VAD implantation were available. One patient had a rightsided hemiplegia, disabling dystonia of the right arm and mild problems with the study of (foreign) language and calculus. A second patient suffered from a left-sided hemiplegia, but fully 
DISCUSSION
In this study, we found that since 2006, 18 patients were supported on VAD and 61% of these children survived to heart transplantation or recovery. The majority of children who died on VAD were struck by thrombo-embolic events. Similarly, lasting neurological damage was caused by thrombo-embolic events as well. Furthermore, we found that, compared with the era before VADs, waiting list mortality decreased from 44 to 21% and mortality was largely related to complications of VAD support. Our study points out that the overall survival of children with end-stage heart failure increases with the availability of VADs, but this comes at a high prize. A significant number of children die on a VAD or have lasting neurological disability. This urges to critically consider the results and to aim for an improvement of outcome in these patients. In this regard, a reflection on the mortality in our VAD patients is relevant. Data from prior studies demonstrated a wide range of mortality in paediatric patients on a VAD, varying from 38 to 6% [9] [10] [11] [12] [13] [20] [21] [22] , placing our outcome on the unfavourable end of the spectrum. Several factors might contribute to mortality in our patient population, of which patient selection may play an important role. The studies with the lowest mortality are those with the most strict inclusion criteria for implantation of a VAD. For example, in the North American IDE-trial, children with significant end-organ dysfunction were excluded. In this study, they found a low mortality rate [10] . Clinical centres that used VADs on a 'compassionate use' basis presented mortality data of 37%, which is more comparable with our findings. They found that the degree of end-organ dysfunction, in particular the severity of renal failure, had an important effect on outcome [12] . Patient profiles of the 'compassionate use' group were much like our patient group in terms of INTERMACS profile and percentage of significant end-organ failure. Other single-centre studies reporting on paediatric VAD outcome, either showed quite similar mortality [21] , were difficult to compare with regard to patient characteristics at implantation of VAD [22] , or showed an encouraging learning curve in demonstrating that mortality decreased to 18% in the last 4 years of their experience [23] . The relatively low mortality found in the IDE trial suggests that favourable patient selection leads to improvement of outcome. Our mortality data may reflect our somewhat prudent policy in implanting VADs in children, resulting in a severely ill patient group with (beginning) end-organ failure. However, we also found that mortality in the non-VAD patients was very low (2/25, 8%) and in the 2 children who died, parents did not consent to VAD implantation. This suggests that, although we implant VADs relatively late in the disease process, we do not lose patients as a result of this conservative policy.
With regard to SAE, we found a significant number of these events during VAD treatment. The most common SAE was formation of thrombus in the system leading to VAD replacement, occurring in 61% of patients. Brancaccio et al. report pump replacement in 52% of patients [23] , similar to Malaisrie et al. who found 50% [21] . The comprehensive study performed by Almond et al. and the single-centre study by Rockett et al. are not clear on this matter [12, 22] . In the days following VAD implantation, 5 patients (28%) developed pericardial effusion necessitating rethoracotomy. This figure is comparable with the rethoracotomy percentages in other studies [22] .
The most alarming serious adverse events are the thromboembolic events, which are even more disconcerting in the face of our relative high number of pump replacements. The limited number of observations did not allow a formal analysis with regard to a possible association between Berlin Heart EXCOR ventricle size and thrombo-embolic events. Considering children below 15 kg as 'small patients', our series included 5 small patients (4 with a ventricle of 25 ml, 1 with a ventricle of 10 ml), 3 patients developed a thrombo-embolic event. In the whole VAD group, we found 7/18 (38%) patients with a thrombo-embolic event, 4/13 (31%) in the patients over 15 kg versus 3/5 (60%) in the small patients. This suggests that, in smaller children, more (lethal) thrombo-embolisms may occur. In the present study, we found thrombo-embolic stroke in 33% of children and thrombo-embolic stroke accounted for 43% of all deaths on VAD. The number of thrombo-embolic strokes in our study is similar to other singlecentre outcomes [21, 22] , but higher than the earlier mentioned 'compassionate use' cohort. [12] . This might suggest that the high stroke rate cannot be fully explained by patient selection only. Preventing thrombo-embolic events is quite challenging. In our hospital, we follow the well-accepted Edmonton protocol [16, 17] . Closer monitoring of coagulation and possible exploration of other anticoagulatory strategies [18] might lead to reduction of thrombo-embolic events.
In spite of a considerable mortality and morbidity in VAD patients, we still believe that a VAD is an acceptable therapeutic tool. Taken into account that survival of heart transplantation patients is unaffected by previous VAD implantation [24] , we are inclined to believe that the positive effect of VAD support on survival in end-stage paediatric heart failure outweighs the disconcerting mortality and morbidity rate. We conclude that optimal timing in placement of a VAD is to be determined for every individual patient and antithrombotic monitoring deserves highest priority. It is clear that we need to continue to closely monitor our results and aim for improvement of outcome. This study has several limitations. First of all, the study is prone to selection bias as a result of its retrospective design. We expect however that selection bias was minimal as we serve as referral hospital, and were to our knowledge, able to evaluate all Dutch paediatric VAD patients. Secondly, the number of patients is small preventing robust statistical analysis. Nevertheless, the trends that we observed in our study are comparable with other reports on the use of VADs in the paediatric age group. Thirdly, we present the cumulative experience over the course of 8 years, reflecting a learning curve of selecting patients as well as surgical and medical management of patients on VAD. Lastly, we reported the outcome of patients from 2 consecutive eras, inherently resulting in a historical comparison. Indeed, our data reflect a growing heart transplantation programme and, over the course of years, the number of patients referred to our hospital and listed for heart transplantation increased accordingly. Nevertheless, patient profiles in the two cohorts were quite similar. In Cohort I, all patients were on the waiting list. In this era, we did not use any form of mechanical support (including ECMO) as a bridge to transplantation. In Cohort II, all patients were on the waiting list or were eligible for heart transplantation at the time of admission for mechanical support. Patients with expected short-time mechanical support, for example patients with myocarditis, were excluded as they were not considered eligible for heart transplantation, except for 1 patient with a protracted disease course (>6 weeks). Therefore, we believe that the data presented in this study reliably describe 'all' patients who were referred to our hospital and who were considered eligible for heart transplantation. This implies that Cohorts I and II are a fair representation of children requiring transplantation in the respective eras, and patient profiles were sufficiently similar to meaningfully compare the two cohorts.
CONCLUSION
We found that, in our hands, 61% of children with end-stage heart failure, supported on VAD, survive to heart transplantation or recovery. This modest survival rate most likely reflects a selection of a severely ill patient population. Although thrombo-embolic events on VAD lead to considerable mortality and morbidity, overall mortality in the children on the waiting list halved since the introduction of VADs. This supports the growing evidence that VADs are an acceptable therapeutic tool to bridge children with end-stage heart failure to transplantation or recovery. Improvement of outcome in these children is to be sought in optimal timing of VAD implantation for every individual patient, and in improvement of anticoagulatory strategies. We expect that, in future years, an increasing number of children with end-stage heart failure will survive, and will be possible candidates for heart transplantation, leaving the need for donor organs critically urgent.
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